The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

ClinicalTrials & Tribulations

Smoldering multiple myeloma: Rethinking the waiting game

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

With the recent FDA approval of daratumumab for high-risk smoldering multiple myeloma, the moment is ripe to revisit the evolution of our understanding of smoldering multiple myeloma. This development not only underscores the growing recognition of early intervention but also invites a broader reflection on the biological insights and therapeutic strategies that have shaped—and continue to shape—this transitional disease state.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
C. Ola Landgren, MD, PhD
Professor of medicine, Chief, Division of Myeloma, Department of Medicine, Director, Sylvester Myeloma Institute, Co-leader, Translational and Clinical Oncology Program, Paul J. DiMare Endowed Chair in Immunotherapy, Sylvester Comprehensive Cancer Center,
University of Miami
Table of Contents

YOU MAY BE INTERESTED IN

Drugs & Targets

FDA accepts NDA for zipalertinib for NSCLC with mutations

FDA has accepted a New Drug Application for zipalertinib for the treatment of patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy, with or without amivantamab. The Prescription Drug User Fee Act target action date is Feb. 27, 2027.
Drugs & Targets

FDA approval of IDE supplement to expand Alpha DaRT IMPACT Trial to patients with pancreatic cancer receiving gemcitabine with abraxane

FDA has approved an Investigational Device Exemption supplement to its U.S. multi-center pancreatic cancer pilot study, known as IMPACT (Intratumoral Pancreatic Alpha Combination Trial), evaluating the safety, feasibility, and efficacy of Alpha DaRT in combination with chemotherapy for patients with newly diagnosed unresectable locally advanced or metastatic pancreatic adenocarcinoma.
Byline
C. Ola Landgren, MD, PhD
Professor of medicine, Chief, Division of Myeloma, Department of Medicine, Director, Sylvester Myeloma Institute, Co-leader, Translational and Clinical Oncology Program, Paul J. DiMare Endowed Chair in Immunotherapy, Sylvester Comprehensive Cancer Center,
University of Miami
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account